Destiny Pharma PLC making significant strides towards phase III evaluation of potential breakthrough C.diff treatment

CEO Neil Clark said: “We have made significant progress since closing the £10.4mln equity funding in December 2020 that enabled the NTCD-M3 acquisition.”   () chief executive Neil Clark said the group has made significant progress preparing its lead asset, NTCD-M3, for a phase III clinical study, which was on track to go ahead next year. […]